BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for endoglycosidase [epc]. First approved in 2025.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEYTRUDA QLEX is a fixed-dose combination of pembrolizumab (a PD-1 checkpoint inhibitor) and berahyaluronidase alfa, a recombinant human hyaluronidase enzyme that enables subcutaneous administration. It blocks programmed death receptor-1 interactions to restore anti-tumor immune responses across multiple cancer indications. The hyaluronidase component allows deeper subcutaneous penetration, improving patient convenience over intravenous KEYTRUDA.
Launch
As a recently approved product, KEYTRUDA QLEX is in early commercial expansion; sales teams and medical affairs will expand to support market penetration against established competitors.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KEYTRUDA QLEX is a high-visibility oncology launch within Merck's dominant PD-1 franchise, offering strong career acceleration for commercial professionals driving subcutaneous adoption. Working on this product positions you at the intersection of Merck's core oncology business and the growing subcutaneous biologics trend, with visibility to senior leadership and clear metrics-driven KPIs.
Brand Manager
Worked on KEYTRUDA QLEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.